CN110128446B - 3,4,5-三甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 - Google Patents
3,4,5-三甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 Download PDFInfo
- Publication number
- CN110128446B CN110128446B CN201910530431.1A CN201910530431A CN110128446B CN 110128446 B CN110128446 B CN 110128446B CN 201910530431 A CN201910530431 A CN 201910530431A CN 110128446 B CN110128446 B CN 110128446B
- Authority
- CN
- China
- Prior art keywords
- indazole
- isoxazole
- substituted spiro
- phenyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical group C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 125000003003 spiro group Chemical group 0.000 title claims abstract description 32
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- YWOYDSXGPUZKBI-UHFFFAOYSA-N 6-bromo-3-(hydroxyiminomethyl)chromen-4-one Chemical compound C1=C(Br)C=C2C(=O)C(C=NO)=COC2=C1 YWOYDSXGPUZKBI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 claims abstract description 9
- CKVVOMLWWOIRIP-UHFFFAOYSA-N O1N=CC=C1.N1N=CC2=CC=CC=C12 Chemical compound O1N=CC=C1.N1N=CC2=CC=CC=C12 CKVVOMLWWOIRIP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 8
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 claims abstract description 6
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- NJKBGOONWJXOJI-UHFFFAOYSA-N 1-phenyl-5-[(3,4,5-trimethoxyphenyl)methyl]-6,7-dihydro-5H-indazol-4-one Chemical compound COC=1C=C(CC2C(C=3C=NN(C=3CC2)C2=CC=CC=C2)=O)C=C(C=1OC)OC NJKBGOONWJXOJI-UHFFFAOYSA-N 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- PCEZXSJBHMOQFT-UHFFFAOYSA-N 6-bromo-4-oxochromene-3-carbaldehyde Chemical compound O1C=C(C=O)C(=O)C2=CC(Br)=CC=C21 PCEZXSJBHMOQFT-UHFFFAOYSA-N 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- UZMOAUHZAQAFKX-UHFFFAOYSA-N 1,5-dihydroindazol-4-one Chemical compound O=C1CC=CC2=C1C=NN2 UZMOAUHZAQAFKX-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PSXCLWPFIRHOJO-UHFFFAOYSA-N 1-phenyl-6,7-dihydro-5h-indazol-4-one Chemical compound O=C1CCCC2=C1C=NN2C1=CC=CC=C1 PSXCLWPFIRHOJO-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- -1 (3,4, 5-trimethoxy)Phenyl Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- XVNBWGGBXOJIDR-UHFFFAOYSA-N 6-bromochromen-4-one Chemical group O1C=CC(=O)C2=CC(Br)=CC=C21 XVNBWGGBXOJIDR-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910530431.1A CN110128446B (zh) | 2019-06-19 | 2019-06-19 | 3,4,5-三甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910530431.1A CN110128446B (zh) | 2019-06-19 | 2019-06-19 | 3,4,5-三甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110128446A CN110128446A (zh) | 2019-08-16 |
CN110128446B true CN110128446B (zh) | 2021-02-09 |
Family
ID=67578163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910530431.1A Active CN110128446B (zh) | 2019-06-19 | 2019-06-19 | 3,4,5-三甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110128446B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103554135B (zh) * | 2013-11-15 | 2016-01-20 | 绍兴文理学院 | 一种含色酮结构异噁唑类去甲斑蝥素衍生物及其制备方法与应用 |
-
2019
- 2019-06-19 CN CN201910530431.1A patent/CN110128446B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110128446A (zh) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109053731B (zh) | 一种对氯取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用 | |
CN108752365A (zh) | 一种含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用 | |
CN110128444B (zh) | 对硝基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110183467B (zh) | 对甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110128446B (zh) | 3,4,5-三甲氧基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110642864B (zh) | 含吡唑结构的螺[吲唑-吡唑啉]衍生物及制备方法与应用 | |
CN110128445B (zh) | 对氯苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110256462B (zh) | 对氟苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110128447B (zh) | 对甲基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN110143971B (zh) | 甲巯基苯基取代含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN106083884B (zh) | 一种d-亮氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106220642B (zh) | 一种l-亮氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN110156812B (zh) | 含色酮结构的螺[吲唑-异噁唑]衍生物及制备方法与应用 | |
CN109232570B (zh) | 一种含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用 | |
CN110759920A (zh) | 对甲氧基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN110734442B (zh) | 3,4,5-三甲氧基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及制备方法与应用 | |
CN110655522B (zh) | 邻氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN110790769B (zh) | 对甲基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN106046019B (zh) | 一种l-缬氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN110724148B (zh) | 对氯苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN106188081B (zh) | 一种d-缬氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN110746431B (zh) | 对甲巯基苯基取代含吡唑结构的螺[吲唑-吡唑啉]衍生物及其制备方法与应用 | |
CN109053732B (zh) | 一种对氟取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用 | |
CN109180675B (zh) | 一种对甲氧基取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用 | |
CN108640929B9 (zh) | 3,4,5-三甲氧基取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211117 Address after: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee after: Jinan Weiyang Technology Co.,Ltd. Address before: 312000 No. 508 West Ring Road, Zhejiang, Shaoxing Patentee before: SHAOXING University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220509 Address after: 211899 floor 3, building 02, life science and technology Island, No. 11, Yaogu Avenue, Jiangbei new area, Nanjing, Jiangsu Patentee after: Xunuo Pharmaceutical (Nanjing) Co.,Ltd. Address before: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee before: Jinan Weiyang Technology Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: 3,4,5-trimethoxyphenyl substituted chromone containing spiro [indazole isoxazole] derivatives and their preparation methods and applications Granted publication date: 20210209 Pledgee: Bank of Nanjing Jiangbei District branch of Limited by Share Ltd. Pledgor: Xunuo Pharmaceutical (Nanjing) Co.,Ltd. Registration number: Y2024980022886 |